Back to search

Article

A randomized trial shows dose-frequency and genotype may determine the therapeutic efficacy of intranasal oxytocin

2020-08-25

Abstract excerpt

<h4>Background</h4> The neuropeptide oxytocin is proposed as a promising therapy for social dysfunction by modulating amygdala-mediated social-emotional behavior. Although clinical trials report some benefits of chronic treatment it is unclear whether efficacy may be influenced by dose frequency or genotype. <h4>Methods</h4> In a randomized, double blind, placebo-controlled pharmaco-fMRI trial (150 male subjects)...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
6ae8226d-647b-56f7-a995-a1188edbfa2a
DOI
10.1101/2020.08.23.20180489
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
A randomized trial shows dose-frequency and genotype may determine the therapeutic efficacy of intranasal oxytocinDOI 10.1101/2020.08.23.20180489
Select a neighboring publication to make it the new centre.